TrialBJU international2020

Ultra-hypofractionated radiation therapy for unfavourable intermediate-risk and high-risk prostate cancer is safe and effective: 5-year outcomes of a phase II trial.

Victor A Macias et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.